en
Scientific article
Open access
English

5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial

Published inAnnals of oncology, vol. 15, no. 5, p. 759-764
Publication date2004
Abstract

A phase I-II multicenter trial was conducted to define the maximum tolerated dose (MTD) according to tolerance and toxicity (primary objective), as well as to describe the clinical activity, in terms of response and survival (secondary objectives), of a combination of 5-fluorouracil (5-FU) in protracted continuous intravenous infusion (p.i.v.) with docetaxel and cisplatin for patients with advanced gastric cancer.

Keywords
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Carcinoma/drug therapy/pathology
  • Cisplatin/administration & dosage
  • Female
  • Fluorouracil/administration & dosage
  • Humans
  • Infusions, Intravenous
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Stomach Neoplasms/drug therapy/pathology
  • Survival Analysis
  • Taxoids/administration & dosage
Citation (ISO format)
ROTH, Arnaud et al. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. In: Annals of oncology, 2004, vol. 15, n° 5, p. 759–764. doi: 10.1093/annonc/mdh187
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal0923-7534
486views
141downloads

Technical informations

Creation2014.11.20. 오후 2:40:00
First validation2014.11.20. 오후 2:40:00
Update time2023.03.14. 오후 10:17:42
Status update2023.03.14. 오후 10:17:42
Last indexation2024.01.16. 오후 2:32:58
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack